ZYNLONTA

This brand name is authorized in Austria, Estonia, Croatia, Ireland, Italy, Lithuania, Romania, United Kingdom, United States

Active ingredients

The drug ZYNLONTA contains one active pharmaceutical ingredient (API):

1 Loncastuximab tesirine UNII 7K5O7P6QIU - LONCASTUXIMAB TESIRINE

Loncastuximab tesirine is an antibody-drug conjugate (ADC) targeting CD19. Upon binding to CD19, loncastuximab tesirine is internalised followed by release of SG3199 via proteolytic cleavage. The released SG3199 binds to the DNA minor groove and forms highly cytotoxic DNA interstrand crosslinks, subsequently inducing cell death. Read about Loncastuximab tesirine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
ZYNLONTA Powder for solution for infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FX22		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX22

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3039139
Country: IT	Agenzia del Farmaco	Identifier(s): 050484017
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097040
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W69620001
Country: US	FDA, National Drug Code	Identifier(s): 79952-110